ROBERT MCKEOWN: Open Payments
NPI 1801414537 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,602 in 139 payments from 13 companies in 2025. Trend: 2023 $2,106 · 2024 $2,157 · 2025 $2,602
Food & beverage: $2,597Education: $5
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $423 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $330 |
| Neurocrine BioSciences, Inc. | 15 | $320 |
| Teva Pharmaceuticals USA, Inc. | 17 | $280 |
| E.R. Squibb & Sons, L.L.C. | 17 | $278 |
| Janssen Pharmaceuticals, Inc | 16 | $251 |
| ABBVIE INC. | 25 | $229 |
| Vanda Pharmaceuticals Inc. | 9 | $228 |
| Lundbeck LLC | 3 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
Products named: CAPLYTA, INGREZZA, ARISTADA, COBENFY, INVEGA SUSTENNA, VRAYLAR, HETLIOZ, UZEDY.
Industry payments across TN — which companies pay providers there.
